Standout Papers

Durvalumab With or Without T... 2012 2026 2016 2021 488
  1. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022)
    Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology
  2. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019)
    Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology
  3. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study (2020)
    Charles M. Rudin, Mark M. Awad et al. Journal of Clinical Oncology
  4. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023)
    Silvia Novello, Dariusz M. Kowalski et al. Journal of Clinical Oncology
  5. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial (2012)
    Martin Reck, Igor Bondarenko et al. Annals of Oncology

Immediate Impact

15 by Nobel laureates 15 from Science/Nature 88 standout
Sub-graph 1 of 21

Citing Papers

Natural killer cell therapies
2024 StandoutNature
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
3 intermediate papers

Works of Alexander Luft being referenced

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
2023 Standout
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
2022 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Alexander Luft 1925 987 156 540 35 2.2k
Alexander Luft 1447 695 147 268 21 1.7k
Martin Palmer 1511 684 101 604 19 2.0k
Raju Titus Chacko 1309 501 153 220 38 1.6k
Alejandro Navarro 1935 1257 298 585 107 2.5k
William J. Geese 2415 1375 447 295 42 2.9k
See Phan 1239 1006 192 342 22 1.8k
Sandrine Hiret 1152 523 97 281 56 1.5k
Libor Havel 1193 948 85 382 51 1.6k
Stefan Diem 2139 603 209 285 31 2.5k
Hui Yu 1790 923 328 228 39 2.3k

All Works

Loading papers...

Rankless by CCL
2026